Login to Your Account

Deals And M&A NEWS

HONG KONG – YL Biologics Ltd. has inked a licensing deal to distribute a biosimilar for the treatment of anemia by Korea’s CJ Healthcare Ltd. in Japan.

Symbiomix Therapeutics LLC, which saw its single asset, Solosec approved by the FDA last month to treat bacterial vaginosis, agreed to a buyout by Lupin Inc., the U.S. subsidiary of Mumbai-based Lupin Ltd., for $150 million, including $50 million up front.

Shares of Kalvista Pharmaceuticals Inc. soared to $15.80 – and closed at $10.19 for a gain of $2.81 after Merck & Co. Inc. agreed to pay a $37 million nonrefundable up-front fee and up to $715 million in milestone payments as part of a collaboration to advance KVD-001, an intravitreal injection candidate to treat DME.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: